홍주형 (한양대학교) | 한빛사논문 > 한빛사

한빛사논문

조회248

한양대학교

CV File 262 kb

J. Control. Release, Feb 11 2025, 380 S0168-3659(25)00114-2 | https://doi.org/10.1016/j.jconrel.2025.02.008 Cutting-edge biotherapeutics and advanced delivery strategies for the treatment of metabolic dysfunction-associated steatotic liver disease spectrum

Juhyeong Hong ^a,b, Yong-Hee Kim^a,b,c

^aDepartment of Bioengineering, Institute for Bioengineering and Biopharmaceutical Research Hanyang University, 04763 Seoul, South Korea
^bEducation and Research Group for Biopharmaceutical Innovation Leader, Hanyang University, 04763 Seoul, South Korea
cCursus Bio Inc., Icure Tower, Gangnam-gu, Seoul 06170, Republic of Korea

Corresponding author : Yong-Hee Kim

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD), a condition with the potential to progress into liver cirrhosis or hepatocellular carcinoma, has become a significant global health concern due to its increasing prevalence alongside obesity and metabolic syndrome. Despite the promise of existing therapies such as thyroid hormone receptor-β (THR-β) agonists, PPAR agonists, FXR agonists, and GLP-1 receptor agonists, their effectiveness is limited by the complexity of the metabolic, inflammatory, and fibrotic pathways that drive MASLD progression, encompassing steatosis, metabolic dysfunction-associated steatohepatitis (MASH), and reversible liver fibrosis. Recent advances in targeted therapeutics, including RNA interference (RNAi), mRNA-based gene therapies, monoclonal antibodies, proteolysis-targeting chimeras (PROTAC), peptide-based strategies, cell-based therapies such as CAR-modified immune cells and stem cells, and extracellular vesicle-based approaches, have emerged as promising interventions. Alongside these developments, innovative drug delivery systems are being actively researched to enhance the stability, precision, and therapeutic efficacy of these biotherapeutics. These delivery strategies aim to optimize biodistribution, improve target-specific action, and reduce systemic exposure, thus addressing critical limitations of existing treatment modalities. This review provides a comprehensive exploration of the underlying biological mechanisms of MASLD and evaluates the potential of these cutting-edge biotherapeutics in synergy with advanced delivery approaches to address unmet clinical needs. By integrating fundamental disease biology with translational advancements, it aims to highlight future directions for the development of effective, targeted treatments for MASLD and its associated complications.

논문정보

형식Research article
게재일2025년 02월 (BRIC 등록일 2025-02-14)
연구진국내 연구진
분야 바이오·의료융합 > 바이오·의료융합 기타

댓글 작성 로그인

CV 열람하기

연락처 보기